ReproNovo announces first participant dosed in EU Phase 2 trial of RPN-002 for embryo implantation
ReproNovo, a clinical-stage biopharmaceutical company committed to addressing critical gaps in male and female fertility as well as women’s health, today announced that the first participant has been dosed in…